177 related articles for article (PubMed ID: 28078985)
1. Designing Isoform-selective Inhibitors Against Classical HDACs for Effective Anticancer Therapy: Insight and Perspectives from In Silico.
Ganai SA
Curr Drug Targets; 2018; 19(7):815-824. PubMed ID: 28078985
[TBL] [Abstract][Full Text] [Related]
2. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
Ganai SA
Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
[TBL] [Abstract][Full Text] [Related]
3. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N; Rashid H; Kalsoom S
Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
[TBL] [Abstract][Full Text] [Related]
4. Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer.
Ononye SN; van Heyst M; Falcone EM; Anderson AC; Wright DL
Pharm Pat Anal; 2012 May; 1(2):207-21. PubMed ID: 24163736
[TBL] [Abstract][Full Text] [Related]
5. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
Qin HT; Li HQ; Liu F
Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.
Ganai SA
Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer.
Kollar J; Frecer V
Curr Pharm Des; 2015; 21(11):1472-502. PubMed ID: 25382430
[TBL] [Abstract][Full Text] [Related]
8. Structure-based virtual screening for novel potential selective inhibitors of class IIa histone deacetylases for cancer treatment.
Elmezayen AD; Kemal Y
Comput Biol Chem; 2021 Jun; 92():107491. PubMed ID: 33930743
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel isoform-selective histone deacetylases 5 and 9 inhibitors through combined ligand-based pharmacophore modeling, molecular mocking, and molecular dynamics simulations for cancer treatment.
Elmezayen AD; Al-Obaidi A; Yelekçi K
J Mol Graph Model; 2021 Jul; 106():107937. PubMed ID: 34049193
[TBL] [Abstract][Full Text] [Related]
10. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
Uba AI; Yelekçi K
J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
[TBL] [Abstract][Full Text] [Related]
11. Non-histone substrates of histone deacetylases as potential therapeutic targets in epilepsy.
Kumar S; Attrish D; Srivastava A; Banerjee J; Tripathi M; Chandra PS; Dixit AB
Expert Opin Ther Targets; 2021 Jan; 25(1):75-85. PubMed ID: 33275850
[No Abstract] [Full Text] [Related]
12. Multi-targeted histone deacetylase inhibitors in cancer therapy.
Ai T; Cui H; Chen L
Curr Med Chem; 2012; 19(4):475-87. PubMed ID: 22204328
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylases as therapeutic targets--from cancer to cardiac disease.
Abend A; Kehat I
Pharmacol Ther; 2015 Mar; 147():55-62. PubMed ID: 25444758
[TBL] [Abstract][Full Text] [Related]
14. Selective Histone Deacetylase Inhibitors with Anticancer Activity.
Ma N; Luo Y; Wang Y; Liao C; Ye WC; Jiang S
Curr Top Med Chem; 2016; 16(4):415-26. PubMed ID: 26268343
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors.
Kashyap K; Kakkar R
Comput Biol Med; 2020 Aug; 123():103850. PubMed ID: 32658783
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Potent and Isoform-selective Histone Deacetylase Inhibitors Using Structure-based Virtual Screening and Biological Evaluation.
Peng Z; Zhao Q; Tian X; Lei T; Xiang R; Chen L; Yang Y
Mol Inform; 2022 Sep; 41(9):e2100295. PubMed ID: 35224862
[TBL] [Abstract][Full Text] [Related]
17. Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms.
Ganai SA; Shanmugam K; Mahadevan V
J Biomol Struct Dyn; 2015; 33(2):374-87. PubMed ID: 24460542
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR (CoMFA, CoMSIA) and Molecular Docking Studies on Histone Deacetylase 1 Selective Inhibitors.
Abdizadeh T; Ghodsi R; Hadizadeh F
Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):365-383. PubMed ID: 28482791
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
Sarkar R; Banerjee S; Amin SA; Adhikari N; Jha T
Eur J Med Chem; 2020 Apr; 192():112171. PubMed ID: 32163814
[TBL] [Abstract][Full Text] [Related]
20. Exploring structural requirements of isoform selective histone deacetylase inhibitors: a comparative
Kashyap K; Kakkar R
J Biomol Struct Dyn; 2021 Feb; 39(2):502-517. PubMed ID: 31900046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
